New drug trial targets genetic flaw in many advanced cancers

NCT ID NCT04639219

Summary

This study is testing whether the drug trastuzumab deruxtecan (T-DXd) can help control advanced solid tumors that have spread and contain specific HER2 gene mutations, regardless of where the cancer started in the body. It is for adults whose cancer has worsened after prior treatments or who have no other good treatment options. The main goal is to see how many patients' tumors shrink significantly and for how long.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS WITH HER2 MUTATION,EG:COLORECTAL,UROTHELIAL,GASTRIC, HEPATOBILIARY,ENDOMETRIAL,MELANOMA,OVARIAN,CERVICAL,SALIVARY GLAND,PANCREATIC,BREAST are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Research Site

    Santa Rosa, California, 95403, United States

  • Research Site

    Muncie, Indiana, 47303, United States

  • Research Site

    Boston, Massachusetts, 02115, United States

  • Research Site

    Boston, Massachusetts, 02215, United States

  • Research Site

    Middletown, New Jersey, 07748, United States

  • Research Site

    Commack, New York, 11725, United States

  • Research Site

    Harrison, New York, 10604, United States

  • Research Site

    New York, New York, 10021, United States

  • Research Site

    Houston, Texas, 77030, United States

  • Research Site

    Fairfax, Virginia, 22031, United States

  • Research Site

    Anderlecht, 1070, Belgium

  • Research Site

    Toronto, CA, M5G 2M9, Canada

  • Research Site

    Copenhagen, 2100, Denmark

  • Research Site

    Bordeaux, 33076, France

  • Research Site

    Lyon, 69008, France

  • Research Site

    Villejuif, 94805, France

  • Research Site

    Milan, 20141, Italy

  • Research Site

    Milan, 20162, Italy

  • Research Site

    Naples, 80131, Italy

  • Research Site

    Chūōku, 104-0045, Japan

  • Research Site

    Kashiwa, 277-8577, Japan

  • Research Site

    Suita-shi, 565-0871, Japan

  • Research Site

    Seoul, 03080, South Korea

  • Research Site

    Seoul, 03722, South Korea

  • Research Site

    Seoul, 06351, South Korea

  • Research Site

    Barcelona, 08035, Spain

  • Research Site

    Madrid, 28041, Spain

  • Research Site

    Madrid, 28050, Spain

  • Research Site

    Pamplona, 31008, Spain

  • Research Site

    Seville, 41013, Spain

Conditions

Explore the condition pages connected to this study.